Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World
Health Organization and the National Hansen's Disease Program consider clofazamine to be
standard therapy for treatment of multibacillary leprosy. In recent years, the availability
of the drug has become limited and is currently available only under a research protocol and
is considered "investigational." Use of Clofazamine in patients presenting with lepromatous
leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other
therapies. This drug will be used prospectively for patients who require treatment of leprosy
as deemed appropriate by a Kaiser Permanente Southern California physician.
Details
Lead Sponsor:
Kaiser Permanente
Collaborator:
Health Resources and Services Administration (HRSA)